<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">The production design basis of most therapeutic mAbs is quite similar
 <sup>
  <xref ref-type="bibr" rid="CR14">14</xref>
 </sup>. Using a platform process for phase 1 production ensures portability to other manufacturing facilities. If there is a need to quickly produce hundreds of thousands of doses (100 kg or more), this common design basis would be key to accomplishing this objective.
</p>
